“This partnership with Cardiac Imaging allows unprecedented access of RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator...
The study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as a randomized, doub...
Real-world evidence (RWE) research results on treatment utilization and pathways in women with menopausal symptoms via poster presentations on the CHAPTE...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
Paratek's successful commercialization platform to advance novel therapies developed organically and through acquisitions Paratek adds 'final-mile' capa...
Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 Corresponding patents have b...
“While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics ...
News Highlights: Brain Bio-Digital Twin technology has the potential to change medical treatment practices by eliminating the need for invasive and cost...
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigim...
Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases...
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. In a new paper published in Nature's Scientific Repo...
What You Need to Know Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA C...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile-- Clover Biopharmaceutica...
© 2025 Biopharma Boardroom. All Rights Reserved.
